Cardioprotective effect of calcineurin inhibition in an animal model of renal disease

European Heart Journal

Volumn 32, Issue 15, 2011, Pages 1935-1945

  Di Marco, Giovana S ^a   Reuter, Stefan ^a   Kentrup, Dominik ^a   Ting, Lu ^a   Ting, Liu ^a   Grabner, Alexander ^a   Jacobi, Annett M ^a   Pavensätdt, Hermann ^a   Baba, Hideo A ^b   Tiemann, Klaus ^a   Brand, Marcus ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Calcineurin inhibition; Cardiovascular protection; Chronic kidney disease; Cyclosporine; Tacrolimus; Vascularization

Indexed keywords

CYCLOSPORIN A; HYDRALAZINE; STROMAL CELL DERIVED FACTOR 1; TACROLIMUS; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; BLOOD VOLUME; CAPILLARY DENSITY; CONTROLLED STUDY; CREATININE CLEARANCE; ECHOCARDIOGRAPHY; GENE EXPRESSION; HEART FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART PROTECTION; HEART VENTRICLE REMODELING; KIDNEY FUNCTION; KIDNEY INJURY; LOW DRUG DOSE; MALE; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; RAT; STEM CELL; UPREGULATION; VASCULARIZATION;

ANIMALS; CALCINEURIN; CHRONIC DISEASE; CYCLOSPORINE; HEART DISEASES; HYPERTROPHY, LEFT VENTRICULAR; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; MALE; NEPHRECTOMY; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; TACROLIMUS; VENTRICULAR REMODELING;

EID: 80051538639     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehq436     Document Type: Article

References (37)

1. Amann K, Wiest G, Zimmer G, Gretz N, Ritz E, Mall G. Reduced capillary density in the myocardium of uremic rats-a stereological study. Kidney Int 1992;42: 1079-1085.
2. Koleganova N, Piecha G, Ritz E, Bekeredjian R, Schirmacher P, Schmitt CP, Gross ML. Interstitial fibrosis and microvascular disease of the heart in uremia: amelioration by a calcimimetic. Lab Invest 2009;89:520-530.
3. Silberberg JS, Barre PE, Prichard SS, Sniderman AD. Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 1989;36:286-290. (Pubitemid 19202488)
4. Hage FG, Venkataraman R, Zoghbi GJ, Perry GJ, DeMattos AM, Iskandrian AE. The scope of coronary heart disease in patients with chronic kidney disease. J Am Coll Cardiol 2009;53:2129-2140.
5. Colella M, Pozzan T. Cardiac cell hypertrophy in vitro: role of calcineurin/NFAT as Ca2+ signal integrators. Ann N Y Acad Sci 2008;1123:64-68. (Pubitemid 351431304)
6. Suzuki J, Bayna E, Li HL, Molle ED, Lew WY. Lipopolysaccharide activates calcineurin in ventricular myocytes. J Am Coll Cardiol 2007;49:491-499. (Pubitemid 46135886)
7. Bueno OF, van Rooij E, Molkentin JD, Doevendans PA, De Windt LJ. Calcineurin and hypertrophic heart disease: novel insights and remaining questions. Cardiovasc Res 2002;53:806-821. (Pubitemid 34261019)
8. Amann K, Ritz E. Microvascular disease-the Cinderella of uraemic heart disease. Nephrol Dial Transplant 2000;15:1493-1503.
9. Makino A, Suarez J, Wang H, Belke DD, Scott BT, Dillmann WH. Thyroid hormone receptor-beta is associated with coronary angiogenesis during pathological cardiac hypertrophy. Endocrinology 2009;150:2008-2015.
10. Cetinkaya BO, Acikgoz G, Ayas B, Aliyev E, Sakallioglu EE. Increased expression of vascular endothelial growth factor in cyclosporin A-induced gingival overgrowth in rats. J Periodontol 2006;77:54-60. (Pubitemid 43949657)
11. van Westrhenen R, Aten J, Hajji N, de Boer OJ, Kunne C, de Waart DR, Krediet RT. Cyclosporin A induces peritoneal fibrosis and angiogenesis during chronic peritoneal exposure to a glucose-based, lactate-buffered dialysis solution in the rat. Blood Purif 2007;25:466-472. (Pubitemid 351194890)
12. Wang CH, Cherng WJ, Yang NI, Hsu CM, Yeh CH, Lan YJ, Wang JS, Verma S. Cyclosporine increases ischemia-induced endothelial progenitor cell mobilization through manipulation of the CD26 system. Am J Physiol Regul Integr Comp Physiol 2008;294:R811-R818. (Pubitemid 351346957)
13. Javadov S, Karmazyn M, Escobales N. Mitochondrial permeability transition pore opening as a promising therapeutic target in cardiac diseases. J Pharmacol Exp Ther 2009;330:670-678.
14. Leshnower BG, Kanemoto S, Matsubara M, Sakamoto H, Hinmon R, Gorman JH 3rd, Gorman RC. Cyclosporine preserves mitochondrial morphology after myocardial ischemia/reperfusion independent of calcineurin inhibition. Ann Thorac Surg 2008;86:1286-1292.
15. Piot C, Croisille P, Staat P, Thibault H, Rioufol G, Mewton N, Elbelghiti R, Cung TT, Bonnefoy E, Angoulvant D, Macia C, Raczka F, Sportouch C, Gahide G, Finet G, André-Fouët X, Revel D, Kirkorian G, Monassier JP, Derumeaux G, Ovize M. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med 2008;359:473-481.
16. Cattran DC, Alexopoulos E, Heering P, Hoyer PF, Johnston A, Meyrier A, Ponticelli C, Saito T, Choukroun G, Nachman P, Praga M, Yoshikawa N. Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome: workshop recommendations. Kidney Int 2007;72:1429-1447. (Pubitemid 350197945)
17. Gaston RS. Chronic calcineurin inhibitor nephrotoxicity: reflections on an evolving paradigm. Clin J Am Soc Nephrol 2009;4:2029-2034.
18. Ghafari A, Makhdoomi K, Ahmadpour P, Afshari AT, Fallah MM, Rad PS. Low-dose versus high-dose cyclosporine induction protocols in renal transplantation. Transplant Proc 2007;39:1219-1222. (Pubitemid 46764866)
19. Moroni G, Doria A, Ponticelli C. Cyclosporine (CsA) in lupus nephritis: assessing the evidence. Nephrol Dial Transplant 2009;24:15-20.
20. Rinaldi S, Sesto A, Barsotti P, Faraggiana T, Sera F, Rizzoni G. Cyclosporine therapy monitored with abbreviated area under curve in nephrotic syndrome. Pediatr Nephrol 2005;20:25-29. (Pubitemid 40057849)
21. Brunner FP, Hermle M, Mihatsch MJ, Thiel G. Effect of cyclosporine in rats with reduced renal mass. Clin Nephrol 1986;25:S148-S154. (Pubitemid 16114299)
22. Mervaala EM, Pere AK, Lindgren L, Laakso J, Teravainen TL, Karjala K, Vapaatalo H, Ahonen J, Karppanen H. Effects of dietary sodium and magnesium on cyclosporin A-induced hypertension and nephrotoxicity in spontaneously hypertensive rats. Hypertension 1997;29:822-827. (Pubitemid 27097991)
23. Oie E, Bjornerheim R, Clausen OP, Attramadal H. Cyclosporin A inhibits cardiac hypertrophy and enhances cardiac dysfunction during postinfarction failure in rats. Am J Physiol Heart Circ Physiol 2000;278:H2115-H2123. (Pubitemid 30439226)
24. Rohini A, Agrawal N, Koyani CN, Singh R. Molecular targets and regulators of cardiac hypertrophy. Pharmacol Res 2010;61:269-280.
25. Shimoyama M, Hayashi D, Takimoto E, Zou Y, Oka T, Uozumi H, Kudoh S, Shibasaki F, Yazaki Y, Nagai R, Komuro I. Calcineurin plays a critical role in pressure overload-induced cardiac hypertrophy. Circulation 1999;100:2449-2454.
26. Rambausek M, Ritz E, Mall G, Mehls O, Katus H. Myocardial hypertrophy in rats with renal insufficiency. Kidney Int 1985;28:775-782. (Pubitemid 16156318)
27. Siedlecki AM, Jin X, Muslin AJ. Uremic cardiac hypertrophy is reversed by rapamycin but not by lowering of blood pressure. Kidney Int 2009;75:800-808.
28. Fathi R, Isbel N, Haluska B, Case C, Johnson DW, Marwick TH. Correlates of subclinical left ventricular dysfunction in ESRD. Am J Kidney Dis 2003;41:1016-1025. (Pubitemid 36532136)
29. Fujimoto S, Kagoshima T, Hashimoto T, Nakajima T, Dohi K. Left ventricular diastolic function in patients on maintenance hemodialysis: comparison with hypertensive heart disease and hypertrophic cardiomyopathy. Clin Nephrol 1994;42: 109-116. (Pubitemid 24247191)
30. Mitsnefes MM, Kimball TR, Border WL, Witt SA, Glascock BJ, Khoury PR, Daniels SR. Impaired left ventricular diastolic function in children with chronic renal failure. Kidney Int 2004;65:1461-1466. (Pubitemid 38406988)
31. Mervaala E, Muller DN, Park JK, Dechend R, Schmidt F, Fiebeler A, Bieringer M, Breu V, Ganten D, Haller H, Luft FC. Cyclosporin A protects against angiotensin II-induced end-organ damage in double transgenic rats harboring human renin and angiotensinogen genes. Hypertension 2000;35:360-366. (Pubitemid 30054200)
32. Vega RB, Bassel-Duby R, Olson EN. Control of cardiac growth and function by calcineurin signaling. J Biol Chem 2003;278:36981-36984. (Pubitemid 37175209)
33. Li Y, Hazarika S, Xie D, Pippen AM, Kontos CD, Annex BH. In mice with type 2 diabetes, a vascular endothelial growth factor (VEGF)-activating transcription factor modulates VEGF signaling and induces therapeutic angiogenesis after hindlimb ischemia. Diabetes 2007;56:656-665. (Pubitemid 46348460)
34. Sasso FC, Torella D, Carbonara O, Ellison GM, Torella M, Scardone M, Marra C, Nasti R, Marfella R, Cozzolino D, Indolfi C, Cotrufo M, Torella R, Salvatore T. Increased vascular endothelial growth factor expression but impaired vascular endothelial growth factor receptor signaling in the myocardium of type 2 diabetic patients with chronic coronary heart disease. J Am Coll Cardiol 2005;46:827-834. (Pubitemid 41224806)
35. Goligorsky MS, Yasuda K, Ratliff B. Dysfunctional endothelial progenitor cells in chronic kidney disease. J Am Soc Nephrol 2010;21:911-919.
36. Jacobi J, Porst M, Cordasic N, Namer B, Schmieder RE, Eckardt KU, Hilgers KF. Subtotal nephrectomy impairs ischemia-induced angiogenesis and hindlimb re-perfusion in rats. Kidney Int 2006;69:2013-2021. (Pubitemid 43924265)
37. Korom S, De Meester I, Maas E, Stein A, Wilker S, Jung F,Weimer R, Brendel MD, Ernst W, Friemann S, Linder R, Grimm H, Padberg W, Scharpé S, Kupiec-Weglinski JW, Schwemmle K. CD26 expression and enzymatic activity in recipients of kidney allografts. Transplant Proc 2002;34:1753-1754.